Global pharma major Lupin Limited (Lupin) announced the launch of Sevelamer Hydrochloride Tablets, 800 mg, having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Nagpur, India.
Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagel® Tablets, 800 mg of Genzyme Corporation.
Sevelamer Hydrochloride Tablets, 800 mg (RLD: Renagel®) had estimated annual sales of USD 75 million in the U.S. (IQVIA MAT December 2021).
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
